Bioventus appoints Mark Singleton as CFO effective March 21, 2022, succeeding Gregory Anglum

Bioventus Inc.

Mark Singleton appointed CFO, effective March 21, 2022; joins from Teleflex Inc.
Base salary of $430,000, annual bonus target 50% of base salary.
Initial equity grants: 74,500 RSUs and options for 223,200 shares, vesting over 4 years.
Cash buyout of unvested Teleflex equity of $81,943; plus sign-on cash for unpaid 2021 bonus.
Former CFO Gregory Anglum to remain through April 2022 to assist transition.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark Singleton

Senior Vice President, Chief Financial Officer and principal accounting officer

BVS · Bioventus Inc.

Effective: 2022-03-21
Filed: February 28, 2022, 6:59 PM ET

On February 28, 2022, Bioventus Inc. (the “Company”) announced that Mark Singleton has been appointed as the Company’s Senior Vice President, Chief Financial Officer and principal accounting officer, effective March 21, 2022, succeeding Gregory Anglum in such role.

Departed

Gregory Anglum

Chief Financial Officer

BVS · Bioventus Inc.

Effective: 2022-03-21
Successor: Mark Singleton
Filed: February 28, 2022, 6:59 PM ET

Mr. Anglum is expected to remain employed with the Company through April 2022, to assist with the transition.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Singleton was appointed as Senior Vice President, Chief Financial Officer and principal accounting officer at Bioventus Inc..

Action: appointed
Role: Senior Vice President, Chief Financial Officer and principal accounting officer

Exact text from the filing

On February 28, 2022, Bioventus Inc. (the “Company”) announced that Mark Singleton has been appointed as the Company’s Senior Vice President, Chief Financial Officer and principal accounting officer, effective March 21, 2022, succeeding Gregory Anglum in such role.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gregory Anglum departed as Chief Financial Officer at Bioventus Inc..

Action: departed
Role: Chief Financial Officer

Exact text from the filing

Mr. Anglum is expected to remain employed with the Company through April 2022, to assist with the transition.

View on SEC.gov

Bioventus Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-057853

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.